279 related articles for article (PubMed ID: 23481417)
1. Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study.
Aaltonen KJ; Virkki LM; Jämsen E; Sokka T; Konttinen YT; Peltomaa R; Tuompo R; Yli-Kerttula T; Kortelainen S; Ahokas-Tuohinto P; Blom M; Nordström DC
Semin Arthritis Rheum; 2013 Aug; 43(1):55-62. PubMed ID: 23481417
[TBL] [Abstract][Full Text] [Related]
2. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
3. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
[TBL] [Abstract][Full Text] [Related]
5. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
6. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
Kim G; Barner JC; Rascati K; Richards K
J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
[TBL] [Abstract][Full Text] [Related]
8. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
[TBL] [Abstract][Full Text] [Related]
10. Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts.
Nikiphorou E; Carpenter L; Morris S; Macgregor AJ; Dixey J; Kiely P; James DW; Walsh DA; Norton S; Young A
Arthritis Rheumatol; 2014 May; 66(5):1081-9. PubMed ID: 24782174
[TBL] [Abstract][Full Text] [Related]
11. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
12. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
Yazici Y; Shi N; John A
Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774
[TBL] [Abstract][Full Text] [Related]
13. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
[TBL] [Abstract][Full Text] [Related]
14. Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register.
Forsblad-d'Elia H; Bengtsson K; Kristensen LE; Jacobsson LT
Rheumatology (Oxford); 2015 Jul; 54(7):1186-93. PubMed ID: 25505001
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
Joensuu JT; Aaltonen KJ; Aronen P; Sokka T; Puolakka K; Tuompo R; Korpela M; Vasala M; Ilva K; Nordström D; Blom M
Rheumatology (Oxford); 2016 Oct; 55(10):1803-11. PubMed ID: 27354689
[TBL] [Abstract][Full Text] [Related]
16. Intensifying treatment of rheumatoid arthritis with combinations of traditional disease-modifying anti-rheumatic drugs among patients with persistent disease did not reduce the need for large joint surgery.
Kononoff A; Heiskanen J; Lumiaho J; Kautiainen H; Kaipiainen-Seppänen O
Scand J Rheumatol; 2007; 36(6):424-7. PubMed ID: 18092262
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
Setoguchi S; Solomon DH; Weinblatt ME; Katz JN; Avorn J; Glynn RJ; Cook EF; Carney G; Schneeweiss S
Arthritis Rheum; 2006 Sep; 54(9):2757-64. PubMed ID: 16947774
[TBL] [Abstract][Full Text] [Related]
18. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
Raaschou P; Simard JF; Neovius M; Askling J;
Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
[TBL] [Abstract][Full Text] [Related]
20. A more active treatment has profound effects on the health status of rheumatoid arthritis (RA) patients: results from a population-based RA register in Malmö, Sweden, 1997-2005.
Söderlin MK; Lindroth Y; Turesson C; Jacobsson LT
Scand J Rheumatol; 2010 May; 39(3):206-11. PubMed ID: 20001765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
